Exelixis, Inc. (NASDAQ:EXEL) today announced that it has extended and
restructured its agreement with Swedish Orphan Biovitrum AB (Sobi) to
support the distribution and commercialization of COMETRIQ ®
(cabozantinib) for progressive, unresectable, locally advanced or
metastatic medullary thyroid cancer (MTC) in the European Union (EU),
Switzerland, Norway, Russia, and Turkey.
Exelon today issued the following statement on the State of Illinois
report on potential nuclear power plant closings prepared in response to
House Resolution 1146:
We thank the state for its attention and work on such an important issue
for Illinois and the future of the state’s energy assets.
MARKHAM, ON--(Marketwired - January 15, 2015) - Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) announced today that the Company has entered into a definitive agreement to acquire the Revera Home Health business from Revera Inc. (the "Vendor"), for $83 million in cash, before working capital adjustments (the "Transaction"). The completion of the Transaction is subject to customary closing conditions and regulatory approvals, including assignment of government contracts, and is expected to close following receipt of regulatory approvals.
The big drop in oil prices may be good for the consumer, and therefore the broader economy, but it's bad enough for Exxon Mobil (XOM) and Chevron (CVX) to tip Dow Jones Industrial Average futures prices into negative territory early Friday.
By Peter Loftus
AbbVie's Viekira Pak, a cocktail of several drugs, cured more than 90% of most common form of hepatitis C
U.S. regulators on Friday approved AbbVie Inc.'s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy to be Approved by the FDA BLINCYTO (Blinatumomab) for Injection Will be Available as a 35 mcg Single use Vial
THOUSAND OAKS, Calif.
Netlist Wins Major Legal Victory in Trade Secret, Breach of Contract Lawsuit Against Diablo Technologies, Inc. in Case Involving ULLtraDIMM SSD In Rare Step, Federal Court Orders a Preliminary Injunction Against Diablo Technologies and its Controller Chips Used in Products by SanDisk, IBM, Lenovo, Huawei, and Supermicro
Ferro Corporation (NYSE: FOE, “Company”) announced today that it has
completed the sale of the majority of the assets of its Polymer
Additives business to Polymer Additives, Inc., a wholly owned portfolio
company of H.I.G. Capital, LLC, for approximately $154 million in cash,
subject to customary working capital and other purchase price
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.